238 related articles for article (PubMed ID: 25605841)
41. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A; Avivi I; Bittner B; Bouabdallah R; Brewster M; Catalani O; Follows G; Haynes A; Hourcade-Potelleret F; Janikova A; Larouche JF; McIntyre C; Pedersen M; Pereira J; Sayyed P; Shpilberg O; Tumyan G
J Clin Oncol; 2014 Jun; 32(17):1782-91. PubMed ID: 24821885
[TBL] [Abstract][Full Text] [Related]
42. Problem-Solving Therapy During Outpatient Stroke Rehabilitation Improves Coping and Health-Related Quality of Life: Randomized Controlled Trial.
Visser MM; Heijenbrok-Kal MH; Van't Spijker A; Lannoo E; Busschbach JJ; Ribbers GM
Stroke; 2016 Jan; 47(1):135-42. PubMed ID: 26585393
[TBL] [Abstract][Full Text] [Related]
43. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
44. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma.
Yared J; Kimball A; Baer MR; Bahrain H; Auerbach M
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):253-7. PubMed ID: 23352637
[TBL] [Abstract][Full Text] [Related]
45. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
[TBL] [Abstract][Full Text] [Related]
46. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
[TBL] [Abstract][Full Text] [Related]
47. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
[TBL] [Abstract][Full Text] [Related]
48. Associations of sense of coherence with psychological distress and quality of life in inflammatory bowel disease.
Freitas TH; Andreoulakis E; Alves GS; Miranda HL; Braga LL; Hyphantis T; Carvalho AF
World J Gastroenterol; 2015 Jun; 21(21):6713-27. PubMed ID: 26074710
[TBL] [Abstract][Full Text] [Related]
49. Predicting general and cancer-related distress in women with newly diagnosed breast cancer.
Gibbons A; Groarke A; Sweeney K
BMC Cancer; 2016 Dec; 16(1):935. PubMed ID: 27914469
[TBL] [Abstract][Full Text] [Related]
50. Health-related quality of life, personality and choice of coping are related in renal cell carcinoma patients.
Beisland E; Beisland C; Hjelle KM; Bakke A; Aarstad AK; Aarstad HJ
Scand J Urol; 2015; 49(4):282-9. PubMed ID: 25515950
[TBL] [Abstract][Full Text] [Related]
51. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
Davis TA; White CA; Grillo-López AJ; Velásquez WS; Link B; Maloney DG; Dillman RO; Williams ME; Mohrbacher A; Weaver R; Dowden S; Levy R
J Clin Oncol; 1999 Jun; 17(6):1851-7. PubMed ID: 10561225
[TBL] [Abstract][Full Text] [Related]
52. Illness perceptions and coping in physical health conditions: A meta-analysis.
Dempster M; Howell D; McCorry NK
J Psychosom Res; 2015 Dec; 79(6):506-13. PubMed ID: 26541550
[TBL] [Abstract][Full Text] [Related]
53. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
Foran JM; Cunningham D; Coiffier B; Solal-Celigny P; Reyes F; Ghielmini M; Johnson PW; Gisselbrecht C; Bradburn M; Matthews J; Lister TA
Ann Oncol; 2000; 11 Suppl 1():117-21. PubMed ID: 10707792
[TBL] [Abstract][Full Text] [Related]
54. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
Amiot A; Lévy M; Copie-Bergman C; Dupuis J; Szablewski V; Le Baleur Y; Baia M; Belhadj K; Sobhani I; Leroy K; Haioun C; Delchier JC
Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
[TBL] [Abstract][Full Text] [Related]
55. Coping, problem solving, depression, and health-related quality of life in patients receiving outpatient stroke rehabilitation.
Visser MM; Heijenbrok-Kal MH; Spijker AV; Oostra KM; Busschbach JJ; Ribbers GM
Arch Phys Med Rehabil; 2015 Aug; 96(8):1492-8. PubMed ID: 25921980
[TBL] [Abstract][Full Text] [Related]
56. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
57. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
[TBL] [Abstract][Full Text] [Related]
58. The relationship between religious coping, psychological distress and quality of life in hemodialysis patients.
Ramirez SP; Macêdo DS; Sales PM; Figueiredo SM; Daher EF; Araújo SM; Pargament KI; Hyphantis TN; Carvalho AF
J Psychosom Res; 2012 Feb; 72(2):129-35. PubMed ID: 22281454
[TBL] [Abstract][Full Text] [Related]
59. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
[TBL] [Abstract][Full Text] [Related]
60. Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
Igarashi T; Ogura M; Itoh K; Taniwaki M; Ando K; Kuroda Y; Yamamoto K; Uike N; Tomita A; Nagai H; Kurosawa M; Mori S; Nawano S; Terauchi T; Ohashi Y; Tobinai K
Int J Hematol; 2016 Dec; 104(6):700-708. PubMed ID: 27714587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
